<DOC>
	<DOC>NCT00833482</DOC>
	<brief_summary>This study assesses the effects of voriconazole, 200 mg, administered twice daily (BID), on the steady-state pharmacokinetics of atazanavir administered as atazanavir/ritonavir, 300/100 mg once daily (QD), in healthy participants with functional CYP2C19 alleles. The study also reviews the effects of atazanavir/ritonavir, 300/100 mg QD, on the pharmacokinetics of voriconazole, 200 mg, BID in healthy participants with functional CYP2C19 alleles.</brief_summary>
	<brief_title>Drug Interactions Between Voriconazole and Atazanavir Coadministered as Atazanavir/Ritonavir in Healthy Participants</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<mesh_term>Voriconazole</mesh_term>
	<criteria>Healthy participants as determined by no clinically significant deviation from normal Body Mass Index (BMI) of 18 to 32 kg/m^2, inclusive. BMI=weight(kg)/height (m)^2 Women who are not of childbearing potential (WOCBP)(ie, who are postmenopausal or surgically sterile) and men, ages 18 to 45 years, inclusive WOCBP Sexually active fertile men not using effective birth control if their partners are WOCBP Proven or suspected acute hepatitis (within 12 months prior to the 1st dose) Any significant acute or chronic medical illness Any gastrointestinal surgery that could impact on the absorption of study drug Smoking more than 5 cigarettes per day History of any hemolytic disorders (including druginduced hemolysis) History of acute or chronic pancreatitis History of hypochlorhydria or achlorhydria Men and women weighing &lt;40 kg Positive blood screen for hepatitis C antibody, hepatitis B surface antigen, or HIV1 or HIV2 antibody Patients with galactose intolerance, Lapp lactase deficiency, or glucosegalactose malabsorption</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>September 2012</verification_date>
</DOC>